WO2023028491A1 - Compositions and methods for treating and preventing lung disease - Google Patents
Compositions and methods for treating and preventing lung disease Download PDFInfo
- Publication number
- WO2023028491A1 WO2023028491A1 PCT/US2022/075356 US2022075356W WO2023028491A1 WO 2023028491 A1 WO2023028491 A1 WO 2023028491A1 US 2022075356 W US2022075356 W US 2022075356W WO 2023028491 A1 WO2023028491 A1 WO 2023028491A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- peptide
- asthma
- purified peptide
- therapeutic agents
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 82
- 239000000203 mixture Substances 0.000 title claims abstract description 77
- 208000019693 Lung disease Diseases 0.000 title claims abstract description 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 324
- 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 claims abstract description 173
- 208000006673 asthma Diseases 0.000 claims abstract description 109
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 29
- 102100027773 Pulmonary surfactant-associated protein A2 Human genes 0.000 claims abstract description 15
- 208000025721 COVID-19 Diseases 0.000 claims abstract description 12
- 150000001413 amino acids Chemical class 0.000 claims description 59
- 239000003814 drug Substances 0.000 claims description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims description 31
- 238000004519 manufacturing process Methods 0.000 claims description 25
- 230000000694 effects Effects 0.000 claims description 24
- 229940124597 therapeutic agent Drugs 0.000 claims description 23
- 230000002757 inflammatory effect Effects 0.000 claims description 20
- 206010014950 Eosinophilia Diseases 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 13
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 239000003937 drug carrier Substances 0.000 claims description 12
- 229940125389 long-acting beta agonist Drugs 0.000 claims description 11
- 229940125369 inhaled corticosteroids Drugs 0.000 claims description 10
- 229940071648 metered dose inhaler Drugs 0.000 claims description 10
- 239000006199 nebulizer Substances 0.000 claims description 10
- 230000001078 anti-cholinergic effect Effects 0.000 claims description 9
- 238000002483 medication Methods 0.000 claims description 9
- 238000012387 aerosolization Methods 0.000 claims description 8
- 210000005265 lung cell Anatomy 0.000 claims description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 7
- 230000002685 pulmonary effect Effects 0.000 claims description 7
- 238000010254 subcutaneous injection Methods 0.000 claims description 7
- 239000007929 subcutaneous injection Substances 0.000 claims description 7
- 208000037874 Asthma exacerbation Diseases 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 6
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 5
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 5
- 239000000556 agonist Substances 0.000 claims description 5
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 claims description 5
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 claims description 5
- 229960004436 budesonide Drugs 0.000 claims description 5
- 229960003728 ciclesonide Drugs 0.000 claims description 5
- 239000003246 corticosteroid Substances 0.000 claims description 5
- 229960001334 corticosteroids Drugs 0.000 claims description 5
- 229960002714 fluticasone Drugs 0.000 claims description 5
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 5
- 229960001361 ipratropium bromide Drugs 0.000 claims description 5
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 claims description 5
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 claims description 5
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 5
- 229960001664 mometasone Drugs 0.000 claims description 5
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 3
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 3
- 229960005139 epinephrine Drugs 0.000 claims description 3
- 206010003557 Asthma exercise induced Diseases 0.000 claims 4
- 206010003559 Asthma late onset Diseases 0.000 claims 4
- 208000004657 Exercise-Induced Asthma Diseases 0.000 claims 4
- 208000024695 exercise-induced bronchoconstriction Diseases 0.000 claims 4
- 235000019504 cigarettes Nutrition 0.000 claims 2
- 239000003344 environmental pollutant Substances 0.000 claims 2
- 231100000719 pollutant Toxicity 0.000 claims 2
- 239000000779 smoke Substances 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 151
- 238000011282 treatment Methods 0.000 abstract description 34
- 230000002265 prevention Effects 0.000 abstract description 6
- 102000007615 Pulmonary Surfactant-Associated Protein A Human genes 0.000 description 170
- 235000001014 amino acid Nutrition 0.000 description 63
- 229940024606 amino acid Drugs 0.000 description 57
- 210000004027 cell Anatomy 0.000 description 57
- 229920001184 polypeptide Polymers 0.000 description 52
- 241000699670 Mus sp. Species 0.000 description 48
- 239000000816 peptidomimetic Substances 0.000 description 27
- 108010063954 Mucins Proteins 0.000 description 26
- 102000015728 Mucins Human genes 0.000 description 26
- 210000003979 eosinophil Anatomy 0.000 description 26
- 210000004072 lung Anatomy 0.000 description 24
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 20
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 20
- -1 etc.) Proteins 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 19
- 150000003839 salts Chemical class 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 18
- 239000002245 particle Substances 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 239000013543 active substance Substances 0.000 description 16
- 238000006467 substitution reaction Methods 0.000 description 16
- 239000003981 vehicle Substances 0.000 description 16
- 238000009472 formulation Methods 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 15
- 238000002560 therapeutic procedure Methods 0.000 description 15
- 101000651017 Homo sapiens Pulmonary surfactant-associated protein A2 Proteins 0.000 description 14
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 14
- 230000010085 airway hyperresponsiveness Effects 0.000 description 14
- 230000004054 inflammatory process Effects 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 108700028369 Alleles Proteins 0.000 description 13
- 230000000172 allergic effect Effects 0.000 description 13
- 208000010668 atopic eczema Diseases 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 230000004199 lung function Effects 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 241000288906 Primates Species 0.000 description 10
- 239000002253 acid Chemical group 0.000 description 10
- 210000001552 airway epithelial cell Anatomy 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 229920000858 Cyclodextrin Polymers 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000002950 deficient Effects 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- 230000002209 hydrophobic effect Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 229960002329 methacholine Drugs 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 238000011260 co-administration Methods 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 238000011577 humanized mouse model Methods 0.000 description 7
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 241001678559 COVID-19 virus Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 229940112141 dry powder inhaler Drugs 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 238000001543 one-way ANOVA Methods 0.000 description 6
- 210000002220 organoid Anatomy 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 239000003380 propellant Substances 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000010361 transduction Methods 0.000 description 6
- 230000026683 transduction Effects 0.000 description 6
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- 101001028244 Onchocerca volvulus Fatty-acid and retinol-binding protein 1 Proteins 0.000 description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000006320 pegylation Effects 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 102200086541 rs1965708 Human genes 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical group CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108090000672 Annexin A5 Proteins 0.000 description 4
- 102000004121 Annexin A5 Human genes 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 210000005006 adaptive immune system Anatomy 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000013276 bronchoscopy Methods 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 239000000428 dust Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000007614 genetic variation Effects 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 235000004554 glutamine Nutrition 0.000 description 4
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 4
- 230000004968 inflammatory condition Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 210000003097 mucus Anatomy 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 230000004962 physiological condition Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000009613 pulmonary function test Methods 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 101150031922 MUC5AC gene Proteins 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 108091005609 SARS-CoV-2 Spike Subunit S1 Proteins 0.000 description 3
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 3
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 3
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 238000006640 acetylation reaction Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000005713 exacerbation Effects 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 108010005636 polypeptide C Proteins 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 235000004400 serine Nutrition 0.000 description 3
- 239000008137 solubility enhancer Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 235000008521 threonine Nutrition 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 235000002374 tyrosine Nutrition 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 2
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 206010001881 Alveolar proteinosis Diseases 0.000 description 2
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102100031673 Corneodesmosin Human genes 0.000 description 2
- 101710139375 Corneodesmosin Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 102000057955 Eosinophil Cationic Human genes 0.000 description 2
- 108700016749 Eosinophil Cationic Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 101000972282 Homo sapiens Mucin-5AC Proteins 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100022496 Mucin-5AC Human genes 0.000 description 2
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 2
- 102100035050 Myeloid-associated differentiation marker Human genes 0.000 description 2
- 101710154183 Myeloid-associated differentiation marker Proteins 0.000 description 2
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 101710176384 Peptide 1 Proteins 0.000 description 2
- 101800005149 Peptide B Proteins 0.000 description 2
- 108010043958 Peptoids Proteins 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 2
- 101150099493 STAT3 gene Proteins 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 208000037883 airway inflammation Diseases 0.000 description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000000326 densiometry Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002611 lead compounds Chemical class 0.000 description 2
- 230000029226 lipidation Effects 0.000 description 2
- 208000027028 long COVID Diseases 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000005065 mining Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000003843 mucus production Effects 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 108010091748 peptide A Proteins 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 229960002052 salbutamol Drugs 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000011191 terminal modification Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012762 unpaired Student’s t-test Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- VPZCEPWZYVGUCQ-ZLELNMGESA-N (2S)-5-(diaminomethylideneamino)-2-(methylamino)pentanoic acid Chemical compound CN[C@@H](CCCN=C(N)N)C(O)=O.CN[C@@H](CCCN=C(N)N)C(O)=O VPZCEPWZYVGUCQ-ZLELNMGESA-N 0.000 description 1
- NMDDZEVVQDPECF-LURJTMIESA-N (2s)-2,7-diaminoheptanoic acid Chemical compound NCCCCC[C@H](N)C(O)=O NMDDZEVVQDPECF-LURJTMIESA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- POGSZHUEECCEAP-ZETCQYMHSA-N (2s)-2-amino-3-(3-amino-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(N)=C1 POGSZHUEECCEAP-ZETCQYMHSA-N 0.000 description 1
- JJWNDJPMAQXKDS-BYPYZUCNSA-N (2s)-5-(diaminomethylideneamino)-2-(2-oxohydrazinyl)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NN=O JJWNDJPMAQXKDS-BYPYZUCNSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- LUTLAXLNPLZCOF-UHFFFAOYSA-N 1-Methylhistidine Natural products OC(=O)C(N)(C)CC1=NC=CN1 LUTLAXLNPLZCOF-UHFFFAOYSA-N 0.000 description 1
- WOXWUZCRWJWTRT-UHFFFAOYSA-N 1-amino-1-cyclohexanecarboxylic acid Chemical compound OC(=O)C1(N)CCCCC1 WOXWUZCRWJWTRT-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- TXHAHOVNFDVCCC-UHFFFAOYSA-N 2-(tert-butylazaniumyl)acetate Chemical compound CC(C)(C)NCC(O)=O TXHAHOVNFDVCCC-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- XNBJHKABANTVCP-UHFFFAOYSA-N 2-amino-3-(diaminomethylideneamino)propanoic acid Chemical compound OC(=O)C(N)CN=C(N)N XNBJHKABANTVCP-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-UHFFFAOYSA-N 2-aminohexanoic acid Chemical group CCCCC(N)C(O)=O LRQKBLKVPFOOQJ-UHFFFAOYSA-N 0.000 description 1
- SAZOSDSFLRXREA-YFKPBYRVSA-N 3,5-dinitro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC([N+]([O-])=O)=C(O)C([N+]([O-])=O)=C1 SAZOSDSFLRXREA-YFKPBYRVSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- 241000494545 Cordyline virus 2 Species 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- 229930028154 D-arginine Natural products 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical class OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 101000864780 Homo sapiens Pulmonary surfactant-associated protein A1 Proteins 0.000 description 1
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101000864822 Mus musculus Pulmonary surfactant-associated protein A Proteins 0.000 description 1
- PSFABYLDRXJYID-VKHMYHEASA-N N-Methylserine Chemical compound CN[C@@H](CO)C(O)=O PSFABYLDRXJYID-VKHMYHEASA-N 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- PSFABYLDRXJYID-UHFFFAOYSA-N N-methyl-DL-serine Natural products CNC(CO)C(O)=O PSFABYLDRXJYID-UHFFFAOYSA-N 0.000 description 1
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 1
- 101150098863 N1 gene Proteins 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 102100032341 PCNA-interacting partner Human genes 0.000 description 1
- 101710196737 PCNA-interacting partner Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102100030060 Pulmonary surfactant-associated protein A1 Human genes 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 101001024637 Severe acute respiratory syndrome coronavirus 2 Nucleoprotein Proteins 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 210000005058 airway cell Anatomy 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000002588 alveolar type II cell Anatomy 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000576 arachnoid Anatomy 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000006334 disulfide bridging Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000048657 human ACE2 Human genes 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000002169 hydrotherapy Methods 0.000 description 1
- 230000035874 hyperreactivity Effects 0.000 description 1
- 230000004047 hyperresponsiveness Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- WDWDWGRYHDPSDS-UHFFFAOYSA-N methanimine Chemical compound N=C WDWDWGRYHDPSDS-UHFFFAOYSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- XJODGRWDFZVTKW-ZCFIWIBFSA-N n-methylleucine Chemical compound CN[C@@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-ZCFIWIBFSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 229920000232 polyglycine polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- ZHNFLHYOFXQIOW-LPYZJUEESA-N quinine sulfate dihydrate Chemical compound [H+].[H+].O.O.[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 ZHNFLHYOFXQIOW-LPYZJUEESA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 238000013424 sirius red staining Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000004878 submucosal gland Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- YSMODUONRAFBET-WHFBIAKZSA-N threo-5-hydroxy-L-lysine Chemical compound NC[C@@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-WHFBIAKZSA-N 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229960004764 zafirlukast Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- compositions and methods for treating and preventing lung disease are provided herein.
- SP-A peptides and uses thereof in the treatment and prevention of lung disease e.g., inflammatory lung disease (e.g., asthma)).
- Asthma is the most common respiratory disease in both children and adults and affects 10% of the world’s population, 25 million people in the US alone. Asthma is a chronic syndrome characterized by airway hyperresponsiveness, inflammation, and intermittent respiratory symptoms. The healthcare burden of asthma is significant, amounting to $81 billion in expenditures yearly in the US when direct care healthcare costs and lost productivity are considered. Despite the considerable costs and increasing prevalence, asthma remains poorly understood and difficult to manage due to the heterogeneity of the disease.
- a significant cause of morbidity and mortality in asthma is an acute exacerbation, which can lead to airway injury, remodeling, lung function decline, and death.
- Most exacerbations are caused by respiratory infections (e.g., rhinovirus or Mycoplasma pneumoniae), and the response to these infections is complex, involving both the innate and adaptive immune systems.
- respiratory infections e.g., rhinovirus or Mycoplasma pneumoniae
- exacerbations are associated with accelerated lung function decline.
- reduced lung function is a risk factor for severe exacerbations, this vicious cycle can promote an exacerbation-prone phenotype of asthma.
- an understanding of the mechanisms driving asthma exacerbations has been a critical barrier to progress in the understanding of asthma pathobiology.
- compositions and methods that allow for the treatment and prevention of lung disease (e.g., inflammatory lung disease (e.g., asthma)), as specified in the independent claims.
- lung disease e.g., inflammatory lung disease (e.g., asthma)
- Embodiments of the invention are given in the dependent claims.
- Embodiments of the present invention can be freely combined with each other if they are not mutually exclusive.
- SP-A Surfactant Protein A
- SP-A is a secreted lipoprotein complex.
- SP-A is an innate immune modulator that is produced and secreted by several types of lung cells (alveolar type II cells, airway club cells, and submucosal gland cells) and serves as the first line of defense against inhaled insults throughout the upper and lower airway (e.g., infectious and/or environmental insults). It acts as a regulator of pathogen phagocytosis and inflammatory processes in the lung.
- Mature SP-A is a hetero-ol igomeric product derived from SP-A1 and SP-A2 genes.
- SP-A2 Gln223Lys i.e., Q223K
- SEQ ID NO: 1 the SP-A wild type sequence
- SP-A is a key regulator of eosinophil degranulation and survival, as well as mucin secretion and type 2 inflammation, and may thereby significantly influence asthma severity.
- SP-A encounters eosinophils in the bronchoalveolar compartment and is a critical regulator of their apoptosis during the resolution phase of inflammatory processes.
- SP-A plays a role in directly inducing apoptosis signaling pathways in eosinophils, which results in the attenuation of allergic phenotypes such as mucin production and eosinophilia.
- SP-A attenuates mucin and IL-6 induced by IL-13 in airway epithelial cells obtained from asthmatic subjects with allergic or type 2 asthma.
- the present invention may feature compositions and methods for treating and preventing lung diseases (e.g., inflammatory lung diseases).
- lung diseases e.g., inflammatory lung diseases
- SP-A peptides and uses thereof in the treatment and prevention of lung disease (e.g., asthma).
- the present invention features methods of treating inflammatory lung diseases in a subject in need thereof.
- the method may comprise administering a therapeutically effective amount of any one of the compositions (e.g., purified peptides) as described herein to the subject.
- the present invention may further feature a purified peptide comprising an amino acid sequence of KEQCVE (SEQ ID NO: 9) for use in a method of treating an inflammatory lung disease in a subject in need thereof.
- the present invention features methods and compositions (e.g., pharmaceutical compositions) for enhancing SP-A activity in a cell.
- the composition e.g., a pharmaceutical composition
- the composition may comprise any one of the purified peptides as described herein and a pharmaceutical carrier.
- the composition is in a preparation for aerosol ization.
- the method may comprise delivering any one of the compositions described herein to a cell (e.g., a lung cell).
- Further embodiments provide a system comprising: a) any one of the compositions described herein; and b) a device for pulmonary delivery of the composition.
- the device is a metered dose inhaler.
- One of the unique and inventive technical features of the present invention is the use of an amino acid sequence peptide comprising KEQCVE (SEQ ID NO: 9) (i.e., the 6-mer).
- KEQCVE SEQ ID NO: 9
- the technical feature of the present invention advantageously provides for inhaled delivery.
- the inclusion of the 6-mer i.e., KEQCVE (SEQ ID NO: 9)
- the activity of the larger peptidomimetic i.e., 10-mers or 20-mers.
- the smaller (i.e., the 6-mer) peptide deposits more deeply in the lungs (i.e., the peptide is able to make it further into the lungs) compared to the larger peptides.
- the peptide described herein enables the replacement and/or augmentation of SP-A inside the lungs. None of the presently known prior references or work has the unique, inventive technical feature of the present invention..
- SP-A Surfactant Protein A
- SP-A is a natural component of the lung lining fluid and serves as the first line of defense.
- Some asthma patients either have no SP-A or damaged SP-A.
- Full-Length SP-A delivered directly to the lungs is not feasible due to its large size and complex structure.
- We first developed a series of 10-20 amino acid peptides derived from the lectin domain of SP-A2 in order to determine the specific region of activity. Findings described herein demonstrate that 10-20 amino acid SP-A peptides reduce airway constriction, a fundamental characteristic of asthma, in two different preclinical mouse models of asthma
- the inventive technical features of the present invention contributed to a surprising result.
- the peptidomimetics that include the 6-mer i.e., KEQCVE (SEQ ID NO: 9)
- impact i.e., decreases
- both eosinophil viability and STAT-signaling which would ultimately be a benefit to a patient with asthma.
- the peptidomimetics that include the 6-mer i.e., KEQCVE (SEQ ID NO: 9)
- the peptidomimetics that include the 6-mer work in two phases: (1) an acute phase to reduce airway mucus production and hyperreactivity to methacholine and (2) a late phase to clear the lung of inflammatory eosinophils and neutrophils.
- the peptidomimetics, including the 6-mer work over a longer duration of time; for example, one dose can last in effectiveness for 7-10 days.
- the peptidomimetics also reduce mucous and pro-inflammatory mediators
- FIG. 1 shows a non-limiting overview of the how the 10-mer (i.e., SEQ ID NO: 4) and/or the 20-mer (i.e., SEQ ID NO: 8) SP-A peptides, as well as, the other SP-A peptides described herein reduce airway constriction, a fundamental characteristic of asthma, in two different preclinical mouse models of asthma. As shown in FIG. 1
- the mechanisms of protective action discovered herein are due to 1) direct interaction with eosinophils, a critical inflammatory cell in asthma, to induce apoptosis and promote their resolution from the airway and 2) direct interaction with epithelial cells which line the lung and participate in the inflammatory process, to inhibit mucin production.
- FIGs. 2A and 2B show the genetic variation in SP-A2 is associated with changes in lung function and asthma control.
- the asthmatic subjects with the 223K/K genotype demonstrate significantly worse asthma control (right panel) and lower lung function (left panel) as compared to the heterozygotes for 223Q/K and major allele (homozygosity for 223Q/Q) genotype.
- FIGs. 3A, 3B, 3C, 3D, 3E, 3F, 3G, and 3H show genetic variation in SP-A2 determines the extent of protection against IL-13 induced inflammation in humanized SP-A transgenic mice.
- BAL cells from IL-13 challenged mice (FIG. 3A), which consisted of macrophages (FIG. 3B), neutrophils (FIG. 3C), and eosinophils (FIG. 3D).
- FIG. 3F shows representative PAS images of each genotype treated with IL-13.
- FIG. 3G and 3H shows Stat3 phosphorylation by Western blot and densitometry from representative lung samples; *p ⁇ 0.05 by One-Way Anova with Tukey’s multiple comparisons.
- FIGs. 4A and 4B show genetic variation in SP-A2 determines the extent of protection against IL-13-induced inflammation from bronchial epithelial cells from asthmatic participants.
- FIG. 4B shows genetic variants of SP-A2 that differ only at position 223 (Q and K) were examined for relative binding to IL-13 relative to extracted human oligomeric control SP-A
- FIGs. 5A, 5B, 5C, and 5D show HDM-challenged SP-A deficient mice treated with SP-A peptides have reduced hallmarks of inflammation.
- FIGs. 6A, 6B, and 6C show the shortened 10AA peptides reduce mucin production (FIG. 6A), and eosinophilia (FIG. 6B) in mouse HDM model, and reduce Mucin (Muc5AC RNA) in human primary cells (6C).
- FIGs. 7A, 7B, 7C, 7D, and 7E show HDM-challenged WT mice treated with SP-A peptides have reduced sensitivity to methacholine challenge.
- FIG. 7A shows WT male mice challenged intranasally with HDM on days 0, 7, and 14. On days 1 , 8 and 15 mice were divided into groups and given either vehicle or SP-A peptides (10-mer (i.e., SEQ ID NO: 4), 25 pg/ml, ⁇ 1 mg/kg body weight) via oropharyngeal instillation. On day 19, pulmonary function tests during a methacholine challenge were performed while mice were under anesthesia.
- FIG. 7B shows total airways resistance (Rrs), FIG.
- FIG. 7C shows newtonian resistance (Rn)
- FIG. 7D shows total airways Elastance (Ers)
- FIGs. 8A and 8B show SP-A peptide protects against airway hyperresponsiveness (AHR) in an IL-13 model.
- FIG. 9 shows IL-13-challenged mice treated with SP-A 10-mer peptide (i.e., SEQ ID NO: 4) have improved lung function.
- WT male mice were challenged with vehicle (saline) or IL-13 (3.9 pg) by oropharyngeal delivery for 3 consecutive days.
- Two hours after each IL-13 challenge mice received either vehicle (saline) or SP-A 10-mer peptide (25 pg/ml; ⁇ 1 mg/kg body weight) via oropharyngeal delivery.
- Pulmonary function tests were conducted on day 4 on a flexiVent machine (SCIREQ) with the negative pressure-driven forced expiration (NPFE) extension.
- SCIREQ flexiVent machine
- NPFE negative pressure-driven forced expiration
- IL-13 challenge resulted in significantly increased Newtonian resistance (Rn) and decreased forced expiratory volumes (FEV) at 0.05 seconds.
- Rn Newtonian resistance
- FEV forced expiratory volumes
- FIG. 10 shows primary human lung epithelial cells treated with SP-A peptides have reduced IL-13 induced MUC5AC gene expression.
- Primary human bronchial epithelial cells derived from normal and asthmatic participants were incubated for 30 minutes with either 20-mer (i.e., SEQ ID NO: 8) or 10-mer (i.e., SEQ ID NO: 8) SP-A peptide (20 pg/ml) before stimulation with IL-13 (10 ng/ml) for 5 days.
- SEQ ID NO: 8 20-mer
- 10-mer i.e., SEQ ID NO: 8
- FIGs. 11A, 11 B, 11C and 11 D show an assessment of BALF eosinophilia over time.
- FIG. 11A shows an OVA model of allergic airways.
- FIG. 11 B shows cell distribution in BALF at 24 hours, 3 days and 5 days post-terminal challenge.
- FIG. 11C shows set change in eosinophil frequencies over time.
- FIG. 11 D shows difference in means at 24 hours and 5 days, unpaired Student’s t-test.
- FIGs. 12A, 12B, 12C, 12D, and 12E show assessment of tissue eosinophilia over time.
- FIG. 12A shows representative bright field images of eosinophils (arrows indicate representative eosinophils) in lung tissue by Sirius red staining (top panel: 40x magnification, bottom panel: 100x magnification) and
- FIG. 12B shows quantification of eosinophil counts at day 5.
- FIG. 12C shows net change in eosinophil frequencies over time.
- FIG. 12D shows difference in means at 24 hours and 5 days, unpaired Student’s t-test, #p ⁇ 0.05, **p ⁇ 0.01 FIG.
- FIGs. 13A, 13B, 13C, and 13D show the evaluation of the ability of SP-A to induce eosinophil apoptosis in mouse and human eosinophils in vitro.
- FIG. 13A shows a time course of viability assessed by Trypan Blue and
- RTCA real-time cell analyzer
- FIGs. 14A, 14B, and 14C show the evaluation of the effect of exogenous SP-A administration on eosinophils in SP-A deficient mice after OVA challenge.
- FIG. 14A shows a schematic of OVA challenge and SP-A rescue.
- FIG. 14B shows representative flow diagrams of eosinophil apoptosis and cell death by Annexin V and PI.
- FIGs. 15A and 15B show the analysis of inflammation in SP-A2 humanized mice in the Ova model. Mice were sensitized and challenged in the Ova model, and BAL cellularity (left panel) was assessed 24 hrs post challenge, and mucin production (right panel) was assessed 7 days post-challenge. Presence of human SP-A 223Q in mice resulted in more protection as determined by less eosinophilia and mucin production as compared to SP-A-/- mice. SP-A 223Q expressing mice had similar BAL eosinophilia and mucin production as compared to WT control mice (that have normal mouse SP-A) after Ova challenge.
- FIGs. 16A and 16B show the analysis of inflammation in mice that receive “therapeutic” SP-A peptides in the HDM model.
- Mice were sensitized and challenged in the HDM model according to common methods. Twenty-four hours after the last challenge, mice received either vehicle, a 20-mer or a 10-mer, that encompassed the active site containing 223Q.
- BAL cellularity (left panel) and mucin production (right panel) were assessed 7 days post challenge to assess the role of SP-A on allergic airway resolution.
- SP-A KO mice have significantly enhanced BAL eosinophilia as compared to WT mice. Both 223Q and 223K mice are somewhat protected in the acute phase of this model.
- FIG. 17 shows SP-A 223Q 10-mer peptides significantly suppress MUCSAC expression following IL-13 exposure in human airway epithelial cells.
- Airway epithelial cells cultured at air liquid interface from two asthmatic participants were exposed to IL-13 alone or IL-13 plus SP-A2 peptide that include the Gin at position 223 in the lectin domain (223Q).
- Full-length oligomeric SP-A that is homozygous at position 223Q/Q was used as a positive control.
- MUCSAC expression was determined by RT-PCR.
- FIG. 18 shows SP-A is significantly decreased in asthmatic patients who are obese. This is potentially a target group for SP-A peptide therapy.
- FIG. 19 shows that in human airway epithelial cells taken from asthma patients the peptides and lead peptidomimetic described herein (i.e., SEQ ID NO: 4 and SEQ ID NO: 8 (peptides); and SEQ ID NO: 12 (peptidomimetic)) reduce a key signaling pathway that is activated in asthma- STAT3. Activation of Stat3 signaling leads to airway inflammation and mucus production which make asthma worse.
- the bottom graph shows peptidomimetic lead (i.e., SEQ ID NO: 12) reduces IL-13 stimulated Stat-3 signaling in airway epithelial cells from asthma patients.
- Bronchial epithelial cells were cultured at an air-liquid interface and differentiated for 14 days.
- Cells were treated basolateral with peptidomimetic lead 867 (i.e., SEQ ID NO: 12) at increasing doses for 1hr, prior to basolateral stimulation with IL-13 (50 ng/ml) for 30 min.
- Total cell lysates were analyzed for STAT3 phosphorylation by Western blot compared with total STAT3 and B-actin.
- FIG. 20 shows a peptidomimetic lead (e.g., SEQ ID NO: 25 or C892) reduces IL-6 stimulated STAT-3 signaling in HEK reporter cells.
- a peptidomimetic lead e.g., SEQ ID NO: 25 or C892
- C892 e.g., SEQ ID NO: 25 or C892
- FIG. 21 shows a peptidomimetic lead (e.g., SEQ ID NO: 12 or C867) reduces MUC5AC expression from airway epithelial cells from 4 participants with type 2 asthma.
- Cells were obtained by bronchoscopy were cultured at an air liquid interface for 14 days. At 14 days the cells differentiate, express cilia and produce mucus.
- Some cells were pretreated with C867 (13.08 pM) for one hour prior to stimulation with IL-13 (10 ng/ml) , a significant stimulus for mucus and mucin gene expression, for five days.
- FIG. 22 shows a peptidomimetic lead (e.g., SEQ ID NO: 25 or C892) reduces bronchoconstriction to methacholine challenge in an asthma model.
- WT C57BL/6 female mice were treated with HDM on days 0,7,14 and 24 hrs after each challenge, some mice received lead compounds (from Table 1).
- AHR to methacholine was performed on day 16. *p ⁇ 0.05 by ANOVA, HDM vs Saline; HDM +Lead compound was not different from saline controls.
- FIG. 23 shows peptidomimetic lead reduces IL-6 stimulated STAT-3 signaling in HEK reporter cells compared to full length SP-A.
- Cells were pre-treated with either full length SP-A or the lead peptide for 30 min at increasing concentrations, prior to stimulation with IL-6 (16 ng/ml) for 18 hrs.
- FIG. 24 shows the structures of SEQ ID NO: 23 comprising a small oligoethyleneglycol linker, Pego.
- SEQ ID NO: 23 comprises 3 Pego units (i.e., Pego3), each with 3 ethyleneglycols connected via diglyme diacid, MW 230 per unit.
- Pego3 Pego units
- Hdc lipid attachment
- FIG. 25 shows SP-A binding to HEK293T lysates over-expressing ACE2.
- FIGs. 27A and 27B show full-length SP-A reduces binding of Spike protein to cells overexpressing ACE2.
- FIG. 28 shows SP-A reduced transduction of S1 protein-pseudotyped lentiviral particles in vitro to cells overexpressing ACE2.
- FIG. 29 shows SP-A attenuates SARS-CoV-2 infection in alveolar organoids.
- Pre-treatment of alveolar organoids with SP-A significantly reduced SARS-CoV-2 N genes expression.
- Data are represented as fold change ⁇ SEM relative to the CoV2 sample.
- No N gene expression was detected in MOCK samples.
- FIG. 30 shows SP-A 20-mer peptides inhibit ACE-2/SPIKE mediated pseudoviral entry.
- polypeptide and “protein” are used interchangeably to refer to a polymer of amino acid residues, comprising natural or non-natural amino acid residues, and are not limited to a minimum length. Thus, peptides, oligopeptides, dimers, multimers, and the like are included within the definition. Both full-length proteins and fragments thereof are encompassed by the definition.
- the terms also include post-translational modifications of the polypeptide, including, for example, glycosylation, sialylation, acetylation, and phosphorylation.
- polypeptide herein also refers to a modified protein such as single or multiple amino acid residue deletions, additions, and substitutions to the native sequence, as long as the protein maintains a desired activity.
- a serine residue may be substituted to eliminate a single reactive cysteine or to remove disulfide bonding or a conservative amino acid substitution may be made to eliminate a cleavage site.
- modifications may be deliberate, as through site-directed mutagenesis, or may be accidental, such as through mutations of hosts, which produce the proteins or errors due to polymerase chain reaction (PCR) amplification.
- peptide refers to a short polymer of amino acids linked together by peptide bonds. In contrast to other amino acid polymers (e.g., proteins, polypeptides, etc.), peptides are of about 50 amino acids or less in length.
- a peptide may comprise natural amino acids, non-natural amino acids, amino acid analogs, and/or modified amino acids.
- a peptide may be a subsequence of naturally occurring protein or a non-natural (synthetic) sequence.
- wildtype refers to a non-mutated version of a gene, allele, genotype, polypeptide, or phenotype, or a fragment of any of these. It may occur in nature or be produced recombinantly.
- variant refers to a nucleic acid molecule or polypeptide that differs from a referent nucleic acid molecule or polypeptide by single or multiple amino acid substitutions, deletions, and/or additions and substantially retains at least one biological activity of the referent nucleic acid molecule or polypeptide.
- peptide mimetic refers to a peptide-like molecule that emulates a sequence derived from a protein or peptide.
- a peptide mimetic or peptidomimetic may contain amino acids and/or non-amino acid components.
- peptidomimetics include chemically modified peptides, peptoids (side chains are appended to the nitrogen atom of the peptide backbone, rather than to the a-carbons), P-peptides (amino group bonded to the p carbon rather than the a carbon), etc.
- a “conservative” amino acid substitution refers to the substitution of an amino acid in a peptide or polypeptide with another amino acid having similar chemical properties, such as size or charge.
- each of the following eight groups contains amino acids that are conservative substitutions for one another: (1) Alanine (A) and Glycine (G); (2) Aspartic acid (D) and Glutamic acid (E); (3) Asparagine (N) and Glutamine (Q); (4) Arginine (R) and Lysine (K); (5) Isoleucine (I), Leucine (L), Methionine (M), and Valine (V); (6) Phenylalanine (F), Tyrosine (Y), and Tryptophan (W); (7) Serine (S) and Threonine (T); and (8) Cysteine (C) and Methionine (M).
- Naturally occurring residues may be divided into classes based on common side chain properties, for example: polar positive (histidine (H), lysine (K), and arginine (R)); polar negative (aspartic acid (D), glutamic acid (E)); polar neutral (serine (S), threonine (T), asparagine (N), glutamine (Q)); non-polar aliphatic (alanine (A), valine (V), leucine (L), isoleucine (I), methionine (M)); non-polar aromatic (phenylalanine (F), tyrosine (Y), tryptophan (W)); proline and glycine; and cysteine.
- a “semi-conservative” amino acid substitution refers to the substitution of an amino acid in a peptide or polypeptide with another amino acid within the same class.
- a conservative or semi-conservative amino acid substitution may also encompass non-naturally occurring amino acid residues that have similar chemical properties to the natural residue. These non-natural residues are typically incorporated by chemical peptide synthesis rather than by synthesis in biological systems. These include, but are not limited to, peptidomimetics and other reversed or inverted forms of amino acid moieties.
- Embodiments herein may, in some embodiments, be limited to natural amino acids, non-natural amino acids, and/or amino acid analogs. Non-conservative substitutions may involve the exchange of a member of one class for a member from another class.
- sequence identity refers to the degree to which two polymer sequences (e.g., peptide, polypeptide, nucleic acid, etc.) have the same sequential composition of monomer subunits.
- sequence similarity refers to the degree with which two polymer sequences (e.g., peptide, polypeptide, nucleic acid, etc.) differ only by conservative and/or semi-conservative amino acid substitutions.
- the “percent sequence identity” is calculated by: (1) comparing two optimally aligned sequences over a window of comparison (e.g., the length of the longer sequence, the length of the shorter sequence, a specified window, etc.), (2) determining the number of positions containing identical (or similar) monomers (e.g., same amino acids occurs in both sequences, similar amino acid occurs in both sequences) to yield the number of matched positions, (3) dividing the number of matched positions by the total number of positions in the comparison window (e.g., the length of the longer sequence, the length of the shorter sequence, a specified window), and (4) multiplying the result by 100 to yield the percent sequence identity or percent sequence similarity.
- a window of comparison e.g., the length of the longer sequence, the length of the shorter sequence, a specified window, etc.
- peptides A and B are both 20 amino acids in length and have identical amino acids at all but 1 position, then peptide A and peptide B have 95% sequence identity. If the amino acids at the non-identical position shared the same biophysical characteristics (e.g., both were acidic), then peptide A and peptide B would have 100% sequence similarity.
- peptide C is 20 amino acids in length and peptide D is 15 amino acids in length, and 14 out of 15 amino acids in peptide D are identical to those of a portion of peptide C, then peptides C and D have 70% sequence identity, but peptide D has 93.3% sequence identity to an optimal comparison window of peptide C.
- percent sequence identity or “percent sequence similarity” herein, any gaps in aligned sequences are treated as mismatches at that position.
- Subject “individual,” “host,” “animal,” and “patient” are used interchangeably herein to refer to mammals, including, but not limited to, rodents, simians, humans, felines, canines, equines, bovines, porcines, ovines, caprines, mammalian laboratory animals, mammalian farm animals, mammalian sport animals, and mammalian pets.
- administering refers to the act of giving a drug, prodrug, or other agent, or therapeutic treatment (e.g., SP-A peptide) to a subject or in vivo, in vitro, or ex vivo cells, tissues, and organs.
- Exemplary routes of administration to the human body can be through space under the arachnoid membrane of the brain or spinal cord (intrathecal), the eyes (ophthalmic), mouth (oral), skin (topical or transdermal), nose (nasal), lungs (inhalant), oral mucosa (buccal), ear, rectal, vaginal, by injection (e.g., intravenously, subcutaneously, intratumorally, intraperitoneally, etc.) and the like.
- injection e.g., intravenously, subcutaneously, intratumorally, intraperitoneally, etc.
- co-administration refers to the administration of at least two agent(s) (e.g., multiple SP-A peptides or an SP-A peptide and another therapeutic agent) or therapies to a subject.
- the co-administration of two or more agents or therapies is concurrent.
- a first agent/therapy is administered prior to a second agent/therapy.
- formulations and/or routes of administration of the various agents or therapies used may vary. The appropriate dosage for co-administration can be readily determined by one skilled in the art.
- agents or therapies when agents or therapies are co-administered, the respective agents or therapies are administered at lower dosages than appropriate for their administration alone.
- co-administration is especially desirable in embodiments where the co-administration of the agents or therapies lowers the requisite dosage of a potentially harmful (e.g., toxic) agent(s), and/or when co-administration of two or more agents results in sensitization of a subject to beneficial effects of one of the agents via co-administration of the other agent.
- Treatment covers any administration or application of a therapeutic for disease in a mammal, including a human, and includes inhibiting the disease, arresting its development, or relieving the disease, for example, by causing regression, or restoring or repairing a lost, missing, or defective function; or stimulating an inefficient process.
- a “pharmaceutically acceptable carrier” refers to a non-toxic solid, semisolid, or liquid filler, diluent, encapsulating material, formulation auxiliary, or carrier conventional in the art for use with a therapeutic agent for administration to a subject.
- a pharmaceutically acceptable carrier is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
- the pharmaceutically acceptable carrier is appropriate for the formulation employed.
- the carrier may be a gel capsule. If the therapeutic agent is to be administered subcutaneously, the carrier ideally is not irritable to the skin and does not cause injection site reaction.
- the present invention features compositions and methods for treating and preventing lung disease.
- lung disease e.g., inflammatory lung disease (e.g., asthma)
- lung disease e.g., inflammatory lung disease (e.g., asthma)
- the present invention features compositions and methods for treating and preventing lung disease (e.g., inflammatory lung disease) using peptides whose sequence is derived from an active region of endogenous human SP-A and comprises the major Q allele at position 223 of the SP-A2 peptide.
- lung disease e.g., inflammatory lung disease
- a composition comprising a peptide comprising, consisting essentially of, or consisting of an amino acid sequence selected from, for example, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or peptides with at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to the peptides is provided.
- the peptide binds to a receptor selected from, for example, FC (CD16/32), Sirp-alpha, TLR-2, EGFR, or MYADM (myeloid associated differentiation marker).
- the present invention may feature a method of treating an inflammatory lung disease (e.g., asthma) in a subject in need thereof.
- the method may comprise administering a therapeutically effective amount of a purified peptide as described herein (e.g., a purified peptide comprising an amino acid sequence of KEQCVE (SEQ ID NO: 9)) to the subject.
- a purified peptide comprising an amino acid sequence of KEQCVE (SEQ ID NO: 9) for use in a method of treating an inflammatory lung disease in a subject in need thereof.
- the present invention may also feature methods and compositions (e.g., pharmaceutical compositions) for enhancing SP-A activity in a cell.
- the composition may comprise any of the purified peptides as described herein and a pharmaceutical carrier.
- the composition e.g., the pharmaceutical composition
- the composition e.g., the pharmaceutical composition
- the composition (e.g., the pharmaceutical composition) comprises a purified peptide comprising an amino acid sequence of (Xaa) n KEQCVE(Xaa) n (SEQ ID NO: 20) and a pharmaceutical carrier; where n ranges from 1-16 amino acids, and Xaa is any natural or non-natural amino acid.
- the composition is in a preparation for aerosolization.
- the method for enhancing SP-A activity in a cell may comprise delivering a composition comprising a purified peptide as described herein (e.g., a peptide comprising an amino acid sequence of KEQCVE (SEQ ID NO: 9)) to a cell (e.g., a lung cell).
- n ranges from 0-20 amino acids. In some embodiments, n ranges from 0-15 amino acids. In some embodiments, n ranges from 0-10 amino acids. In some embodiments, n ranges from 0-5 amino acids. In some embodiments, n ranges from 0-1 amino acids. In some embodiments, n ranges from 1-20 amino acids. In some embodiments, n ranges from 1-15 amino acids. In some embodiments, n ranges from 1-10 amino acids. In some embodiments, n ranges from 1-5 amino acids. In some embodiments, n ranges from 4-20 amino acids. In some embodiments, n ranges from 4-15 amino acids. In some embodiments, n ranges from 4-10 amino acids.
- n ranges from 4-5 amino acids. In some embodiments, n ranges from 5-20 amino acids. In some embodiments, n ranges from 5-15 amino acids. In some embodiments, n ranges from 5-10 amino acids. In some embodiments, n ranges from 10-20 amino acids. In some embodiments, n ranges from 10-15 amino acids. In some embodiments, n ranges from 15-20 amino acids.
- Table 1 shows non-limiting examples of purified peptides that may be used in accordance with compositions and methods described herein.
- the aforementioned peptides comprise, consist essentially of, or consists of an amino acid sequence of at least 80% (e.g., 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%) identity to the peptides provided.
- the composition is a pharmaceutical composition.
- the composition comprises a pharmaceutically acceptable carrier.
- the composition is formulated for pulmonary delivery.
- the aforementioned peptides may comprise, consist essentially of, or consists of an amino acid sequence of at least 95%, 90%, 85%, 83%, 80%, 75%, or 70% identity to the peptides provided.
- Nle refers to Norleucine, an amino acid with the formula CH 3 (CH2) 3 CH(NH2)CO 2 H (or the systematic name is 2-aminohexanoic acid)
- Pego3 refers to a PEGylation which is a biochemical modification process of bioactive molecules with polyethylene glycol (PEG), which lends several desirable properties to proteins/peptides, antibodies, and vesicles considered to be used for therapy or genetic modification of cells. PEGylation is routinely achieved by the incubation of a reactive derivative of PEG with the target molecule.
- PEGylation can also provide water solubility to hydrophobic drugs and proteins. Having proven its pharmacological advantages and acceptability, PEGylation technology is the foundation of a growing multibillion-dollar industry. Additionally, an acetyl (Ac) modification may be used to closely match that of the native protein and to stabilize the peptidomimetic against enzymatic degradation by exopeptidases.
- Compound C892 (i.e., SEQ ID NO: 25) is a stable isostere analog of C867 (i.e., SEQ ID NO: 12) and both show near identical activities in all assays in which they were tested.
- Compounds C939 i.e., SEQ ID NO: 23
- C940 i.e., SEQ ID NO: 24
- Hdc PEGylation and lipidation
- the peptides described herein are modified by addition of an amine or acid group to the C-terminal, and acetylation or addition of a histidine (H) to the N-terminal.
- the peptides described herein are modified by addition of an acid to the N-terminal.
- acids that may be used to modify the N-terminal of the peptides described herein may include but are not limited to a hydroxyl group (-OH), carboxyl group/carboxylic acid group (COOH), or a combination thereof.
- the peptides described herein are modified with a lipid group and the C-terminal and/or N-terminal.
- the cell is a lung cell.
- the composition is for pulmonary delivery.
- the present invention features a system comprising a pharmaceutical composition as described herein and a device for pulmonary delivery of said composition.
- said device is a metered dose inhaler or a nebulizer.
- the compositions described herein are for treating or preventing asthma, COPD, or COVID-19.
- the present invention features a method comprising delivering a composition comprising a peptide as described herein to a cell (e.g., a lung cell) in a subject.
- the peptide comprises an amino acid sequence of KEQCVE (SEQ ID NO: 9).
- the peptide comprises an amino acid sequence of KEQCVE(Xaa)n (SEQ ID NO: 10).
- the peptide comprises an amino acid sequence of (Xaa)nKEQCVE(Xaa)n (SEQ ID NO: 20).
- Delivering the peptide to the cell (e.g., the lung cell) in the subject may result in enhancing SP-A activity in the cell and/or treating or preventing asthma, COPD, or COVID-19 in the subject (i.e., patient) or participant.
- the composition is delivered to the cell (e.g., the lung cell) via a metered inhaler or a nebulizer.
- compositions described herein reduce mucin production and/or reduce eosinophilia in said cell or lung tissue.
- said subject is obese.
- said peptide binds to a receptor, such as FC (CD16/32), Sirp-alpha, TLR-2, or EGFR.
- an SP-A peptide comprises conservative, semi-conservative, and/or non-conservative substitutions relative to the peptides described herein (e.g., at positions involved in SP-A signaling or positions not involved in SP-A signaling).
- Embodiments are not limited to specific substitutions.
- the peptides described herein are further modified (e.g., substitution, deletion, or addition of standard amino acids; chemical modification, etc.). Modifications that are understood in the field include N-terminal modification, C-terminal modification (which protects the peptide from proteolytic degradation), alkylation of amide groups, hydrocarbon “stapling” (e.g., to stabilize alpha-helix conformations).
- the peptides described herein may be modified by conservative residue substitutions, for example, of the charged residues (K to R, R to K, D to E, and E to D).
- such conservative substitutions provide subtle changes, for example, to the receptor binding sites with the goal of improving specificity and/or biological activity.
- Modifications of the terminal carboxy group include, without limitation, the amide, lower alkyl amide, constrained alkyls (e.g. branched, cyclic, fused, adamantyl) alkyl, dialkyl amide, and lower alkyl ester modifications.
- Lower alkyl is C1-C4 alkyl.
- one or more side groups, or terminal groups may be protected by protective groups known to the ordinarily-skilled peptide chemist.
- the a-carbon of an amino acid may be mono- or dimethylated.
- one or more intra-peptide disulfide bonds are introduced (e.g., between two cysteines within the peptide.
- the presence of an intra-peptide disulfide bond may stabilize the peptide.
- Any embodiments described herein may comprise peptidomimetics corresponding to the peptides described herein with various modifications that are understood in the field.
- residues in the peptide sequences described herein may be substituted with amino acids having similar characteristics (e.g., hydrophobic to hydrophobic, neutral to neutral, etc.) or having other desired characteristics (e.g., more acidic, more hydrophobic, less bulky, more bulky, etc.).
- non-natural amino acids or naturally-occurring amino acids other than the standard 20 amino acids are substituted in order to achieve desired properties.
- residues having a side chain that is positively charged under physiological conditions are substituted with a residue including, but not limited to: lysine, homolysine, 5-hydroxylysine, homoarginine, 2,4-diaminobutyric acid, 3-homoarginine, D-arginine, arginal (-COOH in arginine is replaced by -CHO), 2-amino-3-guanidinopropionic acid, nitroarginine (N(G)-nitroarginine), nitrosoarginine (N(G)-nitrosoarginine), methylarginine (N-methylarginine), e-N-methyllysine, allo-hydroxylysine, 2,3-diaminopropionic acid, 2,2'-diaminopimelic acid, ornithine, sym-dimethylarginine, asym-dimethylarginine,
- a neutral residue is a residue having a side chain that is uncharged under physiological conditions.
- a polar residue preferably has at least one polar group in the side chain.
- polar groups are selected from hydroxyl, sulfhydryl, amine, amide and ester groups or other groups which permit the formation of hydrogen bridges.
- residues having a side chain that is neutral/polar under physiological conditions are substituted with a residue including, but not limited to: asparagine, cysteine, glutamine, serine, threonine, tyrosine, citrulline, N-methylserine, homoserine, allo-threonine and 3,5-dinitro-tyrosine, and 3-homoserine.
- Residues having a non-polar, hydrophobic side chain are residues that are uncharged under physiological conditions, preferably with a hydropathy index above 0, particularly above 3.
- non-polar, hydrophobic side chains are selected from alkyl, alkylene, alkoxy, alkenoxy, alkylsulfanyl and alkenylsulfanyl residues having from 1 to 10, preferably from 2 to 6, carbon atoms, or aryl residues having from 5 to 12 carbon atoms.
- residues having a non-polar, hydrophobic side chain are, or residues where a non-polar, hydrophobic side chain is desired, are substituted with a residue including, but not limited to: leucine, isoleucine, valine, methionine, alanine, phenylalanine, N-methylleucine, tert-butylglycine, octylglycine, cyclohexylalanine, p-alanine, 1 -aminocyclohexylcarboxylic acid, N-methylisoleucine, norleucine, norvaline, and N-methylvaline.
- peptides and polypeptides are isolated and/or purified (or substantially isolated and/or substantially purified). Accordingly, in such embodiments, peptides and/or polypeptides are provided in substantially isolated form. In some embodiments, peptides and/or polypeptides are isolated from other peptides and/or polypeptides as a result of solid phase peptide synthesis, for example. Alternatively, peptides and/or polypeptides can be substantially isolated from other proteins after cell lysis from recombinant production. Standard methods of protein purification (e.g., HPLC) can be employed to substantially purify peptides and/or polypeptides.
- Standard methods of protein purification e.g., HPLC
- the present invention provides the preparation of peptides and/or polypeptides in a number of formulations, depending on the desired use.
- the polypeptide is substantially isolated (or even nearly completely isolated from other proteins)
- it can be formulated in a suitable medium solution for storage (e.g., under refrigerated conditions or under frozen conditions).
- suitable medium solution for storage e.g., under refrigerated conditions or under frozen conditions.
- Such preparations may contain protective agents, such as buffers, preservatives, cryoprotectants (e.g., sugars such as trehalose), etc.
- the form of such preparations can be solutions, gels, etc.
- peptides and/or polypeptides are prepared in lyophilized form.
- preparations can include other desired agents, such as small molecules or other peptides, polypeptides, or proteins. Indeed, such a preparation comprising a mixture of different embodiments of the peptides and/or polypeptides described here may be provided.
- a preparation comprising a mixture of different embodiments of the peptides and/or polypeptides described here may be provided.
- a peptidomimetic is characterized by an entity that retains the polarity (or non-polarity, hydrophobicity, etc.), three-dimensional size, and functionality (bioactivity) of its peptide equivalent but wherein all or a portion of the peptide bonds have been replaced (e.g., by more stable linkages).
- ‘stable’ refers to being more resistant to chemical degradation or enzymatic degradation by hydrolytic enzymes.
- the bond which replaces the amide bond conserves some properties of the amide bond (e.g., conformation, steric bulk, electrostatic character, capacity for hydrogen bonding, etc.).
- Suitable amide bond surrogates include, but are not limited to: N-alkylation (Schmidt, R. et al., Int. J. Peptide Protein Res., 1995, 46,47; herein incorporated by reference in its entirety), retro-inverse amide (Chorev, M. and Goodman, M., Acc. Chem. Res, 1993, 26, 266; herein incorporated by reference in its entirety), thioamide (Sherman D. B. and Spatola, A. F. J. Am. Chem. Soc., 1990, 112, 433; herein incorporated by reference in its entirety), thioester, phosphonate, ketomethylene (Hoffman, R. V. and Kim, H. O. J. Org.
- peptidomimetics may involve the replacement of larger structural moieties with di- or tripeptidomimetic structures, and in this case, mimetic moieties involving the peptide bond, such as azole-derived mimetics may be used as dipeptide replacements.
- Suitable peptidomimetics include reduced peptides where the amide bond has been reduced to a methylene amine by treatment with a reducing agent (e.g. borane or a hydride reagent such as lithium aluminum-hydride); such a reduction has the added advantage of increasing the overall cationicity of the molecule.
- a reducing agent e.g. borane or a hydride reagent such as lithium aluminum-hydride
- the peptides and the polypeptides encompassing a substantially alpha helical peptide region that are disclosed herein may be further derivatized by chemical alterations, such as amidation, glycosylation, acylation, sulfation, phosphorylation, acetylation, and cyclization.
- chemical alterations can be imparted through chemical or biochemical methodologies, as well as through in vivo processes, or any combination thereof.
- peptidomimetics include peptoids formed, for example, by the stepwise synthesis of amide-functionalized polyglycines.
- Some peptidomimetic backbones will be readily available from their peptide precursors, such as peptides that have been permethylated; suitable methods are described by Ostresh, J. M. et al. in Proc. Natl. Acad. Sci. USA (1994) 91 , 11138-11142; herein incorporated by reference in its entirety.
- the peptides and polypeptides described herein may be prepared as salts with various inorganic and organic acids and bases.
- Such salts include salts prepared with organic and inorganic acids, for example, with HCI, HBr, H2SO4, H3PO4, trifluoroacetic acid, acetic acid, formic acid, methanesulfonic acid, toluenesulfonic acid, maleic acid, fumaric acid and camphorsulfonic acid.
- Salts prepared with bases include ammonium salts, alkali metal salts, e.g. sodium and potassium salts, alkali earth salts, e.g. calcium and magnesium salts, and zinc salts.
- the salts may be formed by conventional means, such as by reacting the free acid or base forms of the product with one or more equivalents of the appropriate base or acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is then removed in vacuo or by freeze-drying or by exchanging the ions of an existing salt for another ion on a suitable ion exchange resin.
- the peptides and polypeptides described herein can be formulated as pharmaceutically acceptable salts and/or complexes thereof.
- Pharmaceutically acceptable salts include acid addition salts such as those containing sulfate, hydrochloride, phosphate, sulfamate, acetate, citrate, lactate, tartrate, succinate, oxalate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, cyclohexylsulfamate and quinate.
- Pharmaceutically acceptable salts can be obtained from acids such as hydrochloric acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, and quinic acid.
- acids such as hydrochloric acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, and quinic acid.
- Such salts may be prepared by, for example, reacting the free acid or base forms of the product with one or more equivalents of the appropriate base or acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is then removed in vacuo or by freeze-drying or by exchanging the ions of an existing salt for another ion on a suitable ion exchange resin.
- compositions disclosed herein may conveniently be provided in the form of formulations suitable for parenteral administration, including subcutaneous, intramuscular, and intravenous administration, nasal administration, pulmonary administration, or oral administration. Suitable formulation of peptides and polypeptides for each such route of administration is described in standard formulation treatises, e.g., Remington's Pharmaceutical Sciences by E. W. Martin. See also Wang, Y. J. and Hanson, M. A. “Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers,” Journal of Parenteral Science and Technology, Technical Report No. 10, Supp. 42:2S (1988).
- a pharmaceutical composition may be administered in the form which is formulated with a pharmaceutically acceptable carrier and optional excipients, adjuvants, etc., in accordance with good pharmaceutical practice.
- the peptide-based pharmaceutical composition may be in the form of a solid, semi-solid or liquid dosage form: such as powder, solution, elixir, syrup, suspension, cream, drops, paste and spray.
- the composition form is determined. In general, it is preferred to use a unit dosage form in order to achieve an easy and accurate administration of the active pharmaceutical peptide or polypeptide.
- the therapeutically effective pharmaceutical compound is present in such a dosage form at a concentration level ranging from about 0.5% to about 99% by weight of the total composition, e.g., in an amount sufficient to provide the desired unit dose.
- the pharmaceutical composition may be administered in single or multiple doses. The particular route of administration and the dosage regimen will be determined by one of skill in keeping with the condition of the individual to be treated and said individual's response to the treatment.
- an peptides-based pharmaceutical composition is provided in a unit dosage form for administration to a subject, comprising a peptides or polypeptide and one or more nontoxic pharmaceutically acceptable carriers, adjuvants or vehicles.
- the amount of the active ingredient that may be combined with such materials to produce a single dosage form will vary depending upon various factors, as indicated above.
- a variety of materials can be used as carriers, adjuvants and vehicles in the composition of the invention, as available in the pharmaceutical art.
- Injectable preparations such as oleaginous solutions, suspensions or emulsions, may be formulated as known in the art, using suitable dispersing or wetting agents and suspending agents, as needed.
- the sterile injectable preparation may employ a nontoxic parenterally acceptable diluent or solvent such as sterile nonpyrogenic water or 1,3-butanediol.
- Suitable vehicles and solvents that may be employed are 5% dextrose injection, Ringer's injection and isotonic sodium chloride injection (as described in the USP/NF).
- sterile, fixed oils may be conventionally employed as solvents or suspending media.
- any bland fixed oil may be used, including synthetic mono-, di- or triglycerides.
- Fatty acids such as oleic acid can also be used in the preparation of injectable compositions.
- peptides and polypeptides described herein may be substantially insoluble in water and sparingly soluble in most pharmaceutically acceptable protic solvents and in vegetable oils.
- cyclodextrins may be added as aqueous solubility enhancers. Cyclodextrins include methyl, dimethyl, hydroxypropyl, hydroxyethyl, glucosyl, maltosyl and maltotriosyl derivatives of alpha-, beta-, and gamma-cyclodextrin.
- An exemplary cyclodextrin solubility enhancer is hydroxypropyl-beta-cyclodextrin (HPBCD), which may be added to any of the above-described compositions to further improve the aqueous solubility characteristics of the peptides or polypeptides.
- HPBCD hydroxypropyl-beta-cyclodextrin
- the composition comprises 0.1% to 20% HPBCD, 1% to 15% HPBCD, or from 2.5% to 10% HPBCD.
- the amount of solubility enhancer employed will depend on the amount of peptide or polypeptide of the present disclosure in the composition.
- the peptides may be formulated in non-aqueous polar aprotic solvents such as DMSO, dimethylformamide (DMF) or N-methylpyrrolidone (NMP).
- compositions of the peptides and polypeptides described herein may be provided in unit dosage form containing an amount of the peptide or polypeptide effective for a single administration.
- Unit dosage forms useful for subcutaneous administration include prefilled syringes and injectors.
- the polypeptide is administered in an amount, expressed as a daily equivalent dose regardless of dosing frequency, of 50 micrograms (“mcg”) per day, 60 mcg per day, 70 mcg per day, 75 mcg per day, 100 mcg per day, 150 mcg per day, 200 mcg per day, or 250 mcg per day. In some embodiments, the polypeptide is administered in an amount of 500 mcg per day, 750 mcg per day, or 1 milligram (“mg”) per day.
- mcg micrograms
- the polypeptide is administered in an amount, expressed as a daily equivalent dose regardless of dosing frequency, of 1-10 mg per day, including 1 mg per day, 1 .5 mg per day, 1 .75 mg per day, 2 mg per day, 2.5 mg per day, 3 mg per day, 3.5 mg per day, 4 mg per day, 4.5 mg per day, 5 mg per day, 5.5 mg per day, 6 mg per day, 6.5 mg per day, 7 mg per day, 7.5 mg per day, 8 mg per day, 8.5 mg per day, 9 mg per day, 9.5 mg per day, or 10 mg per day.
- the polypeptide is administered on a monthly dosage schedule. In other embodiments, the polypeptide is administered biweekly.
- the polypeptide is administered weekly. In certain embodiments, the polypeptide is administered daily (“QD”). In select embodiments, the polypeptide is administered twice a day (“BID”). In typical embodiments, the polypeptide is administered for at least 3 months, at least 6 months, at least 12 months, or more. In some embodiments, the polypeptide is administered for at least 18 months, 2 years, 3 years, or more.
- compositions are formulated for administration by any suitable route, including but not limited to, orally (e.g., such as in the form of tablets, capsules, granules or powders), sublingually, buccally, parenterally (such as by subcutaneous, intravenous, intramuscular, intradermal, or intrasternal injection or infusion (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions, etc.)), nasally (including administration to the nasal membranes, such as by inhalation spray), topically (such as in the form of a cream or ointment), transdermally (such as by transdermal patch), rectally (such as in the form of suppositories), etc.
- orally e.g., such as in the form of tablets, capsules, granules or powders
- parenterally such as by subcutaneous, intravenous, intramuscular, intradermal, or intrasternal injection or infusion (e.g., as sterile
- the pharmaceutical compositions of this invention are suitable for inhaled administration.
- Suitable pharmaceutical compositions for inhaled administration will typically be in the form of an aerosol or a powder.
- Such compositions are generally administered using well-known delivery devices, such as a nebulizer inhaler, a metered-dose inhaler (MDI), a dry powder inhaler (DPI) or a similar delivery device.
- MDI metered-dose inhaler
- DPI dry powder inhaler
- the pharmaceutical composition comprising the active agent is administered by inhalation using a nebulizer inhaler.
- a nebulizer inhaler typically produce a stream of high velocity air that causes the pharmaceutical composition comprising the active agent to spray as a mist that is carried into the patient's respiratory tract.
- the active agent when formulated for use in a nebulizer inhaler, is typically dissolved in a suitable carrier to form a solution.
- the active agent can be micronized and combined with a suitable carrier to form a suspension of micronized particles of respirable size, where micronized is typically defined as having about 90% or more of the particles with a diameter of less than about 10 .mu.m.
- Suitable nebulizer devices are provided commercially, for example, by PARI GmbH (Starnberg, German). Other nebulizer devices include Respimat (Boehringer Ingelheim) and those disclosed, for example, in U.S. Pat. No. 6,123,068 to Lloyd et al. and WO 97/12687 (Eicher et al.).
- a representative pharmaceutical composition for use in a nebulizer inhaler comprises an isotonic aqueous solution comprising a SP-A peptide or a pharmaceutically acceptable salt or solvate or stereoisomer thereof.
- the pharmaceutical composition comprising the active agent is administered by inhalation using a dry powder inhaler.
- dry powder inhalers typically administer the active agent as a free-flowing powder that is dispersed in a patient's air-stream during inspiration.
- the active agent is typically formulated with a suitable excipient such as lactose or starch.
- a representative pharmaceutical composition for use in a dry powder inhaler comprises dry lactose having a particle size between about 1 pm and about 100 pm and micronized particles of SP-A peptide, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof.
- Such a dry powder formulation can be made, for example, by combining the lactose with the active agent and then dry blending the components.
- the active agent can be formulated without an excipient.
- the pharmaceutical composition is then typically loaded into a dry powder dispenser, or into inhalation cartridges or capsules for use with a dry powder delivery device.
- dry powder inhaler delivery devices include Diskhaler (GlaxoSmithKline, Research Triangle Park, N.C.) (see, e.g., U.S. Pat. No. 5,035,237 to Newell et al.); Diskus (GlaxoSmithKline) (see, e.g., U.S. Pat. No.
- the pharmaceutical composition comprising the active agent is administered by inhalation using a metered-dose inhaler.
- metered-dose inhalers typically discharge a measured amount of the active agent or a pharmaceutically acceptable salt or solvate or stereoisomer thereof using compressed propellant gas.
- pharmaceutical compositions administered using a metered-dose inhaler typically comprise a solution or suspension of the active agent in a liquefied propellant.
- Any suitable liquefied propellant may be employed including chlorofluorocarbons, such as CCI.sub.3F, and hydrofluoroalkanes (HFAs), such as 1 ,1 ,1 ,2-tetrafluoroethane (HFA 134a) and 1 ,1,1 ,2,3,3,3-heptafluoro-n-propane, (HFA 227).
- chlorofluorocarbons such as CCI.sub.3F
- HFAs hydrofluoroalkanes
- HFA 134a 1 ,1 ,1 ,2-tetrafluoroethane
- HFA 227 1 ,1,1 ,2,3,3,3-heptafluoro-n-propane
- co-solvents such as ethanol or pentane
- surfactants such as sorbitan trioleate, oleic acid, lecithin, and glycerin.
- a representative pharmaceutical composition for use in a metered-dose inhaler comprises from about 0.01% to about 5% by weight of a compound of SP-A peptide or a pharmaceutically acceptable salt or solvate or stereoisomer thereof; from about 0% to about 20% by weight ethanol; and from about 0% to about 5% by weight surfactant; with the remainder being an HFA propellant.
- compositions are typically prepared by adding chilled or pressurized hydrofluoroalkane to a suitable container containing the active agent, ethanol (if present) and the surfactant (if present).
- the active agent is micronized and then combined with the propellant.
- the formulation is then loaded into an aerosol canister, which forms a portion of a metered-dose inhaler device.
- metered-dose inhaler devices developed specifically for use with HFA propellants are provided in U.S. Pat. No. 6,006,745 to Marecki and U.S. Pat. No. 6,143,277 to Ashurst et al.
- a suspension formulation can be prepared by spray drying a coating of surfactant on micronized particles of the active agent. See, for example, WO 99/53901 (Glaxo Group Ltd.) and WO 00/61108 (Glaxo Group Ltd.), the disclosures of which are incorporated in their entirety herein by reference.
- peptides/polypeptides are provided in pharmaceutical compositions and/or co-administered (concurrently or in series) with one or more additional therapeutic agents.
- additional agents may be for the treatment or prevention of lung inflammation (e.g., asthma).
- Additional agents may include, but are not limited to: short-acting beta2-adrenoceptor agonists (SABA), such as salbutamol (albuterol USAN); long acting beta agonist (LABA) such as salmeterol and formoterol anticholinergic medications, such as ipratropium bromide, inhaled epinephrine, inhaled corticosteroids such as budesonide, fluticasone, mometasone or ciclesonide, systemic corticosteroids such as prednisone or methylprednisolone; leukotriene receptor antagonists (e.g., montelukast and zafirlukast); or combinations thereof.
- SABA beta2-adrenoceptor agonists
- LAA long acting beta agonist
- corticosteroids such as budesonide, fluticasone, mometasone or ciclesonide
- leukotriene receptor antagonists e.g.,
- kits for treating patients suffering from (or at risk of) lung disease e.g., asthma
- lung disease e.g., asthma
- patients are obese or are not obese can benefit.
- subjects are identified as having an SP-A genotype associated with an increased risk of asthma or severe asthma (e.g., those genotypes described herein).
- a pharmaceutical composition comprising at least one SP-A peptide or polypeptide described herein is delivered to such a patient in an amount and at a location sufficient to treat the condition.
- peptides and/or polypeptides can be delivered to the patient systemically or locally, and it will be within the ordinary skill of the medical professional treating such patient to ascertain the most appropriate delivery route, time course, and dosage for treatment.
- Non-limiting examples of disease conditions having inflammation associated therewith include infection-related or non-infectious inflammatory conditions in the lung (e.g., asthma, sepsis, chronic obstructive pulmonary disease (COPD), COVID-19, lung infections, Respiratory Distress Syndrome, bronchopulmonary dysplasia, etc.); infection-related or non-infectious inflammatory conditions in other organs (e.g., colitis, Inflammatory Bowel Disease, diabetic nephropathy, hemorrhagic shock); inflammation-induced cancer (i.e., cancer progression in patients with colitis or Inflammatory Bowel Disease); and the like.
- infection-related or non-infectious inflammatory conditions in the lung e.g., asthma, sepsis, chronic obstructive pulmonary disease (COPD), COVID-19, lung infections, Respiratory Distress Syndrome, bronchopulmonary dysplasia, etc.
- infection-related or non-infectious inflammatory conditions in other organs e.g., colitis,
- Example 1 demonstrates the genotype of SP-A at position 223 affects lung function and asthma control.
- Previous studies have shown that SP-A derived from asthmatic subjects is dysfunctional in regulating inflammatory conditions, such as IL-8 and MUCSAC production.
- FIG. 15A shows of the 53 asthmatics screened, those that are homozygous for the minor allele (SP-A2 K223K) have lower lung function (FEV1%) than those subjects with the Q223Q or Q223K genotype.
- this cohort of asthmatic subjects demonstrate worse asthma control (asthma control questionnaire; ACQ) than asthmatics with the AC or CC genotype (FIG. 15B).
- SP-A humanized mice exhibit different phenotypes in an allergic model.
- SP-A humanized mice that express either the SP-A223Q (major allele) or SP-A223K (minor allele) were generated. It was discovered that when challenged in the ova model of allergic airways disease the SP-A223Q allele confers more protection as compared to the SP-A223K allele.
- FIG. 15A shows SP-A223Q mice have significantly decreased eosinophilia as compared to mice deficient in SP-A 24 hrs post challenge and they also have significantly reduced mucin production (PAS scores) 7 days post challenge (FIG. 15B).
- SP-A peptides that encompass the 223Q active site attenuate airway eosinophils and mucin production in an allergic model. Since asthmatic subjects harboring the 223K (minor) allele had worse asthma control and lung function as compared to individuals with the 223Q (major) allele and since similar findings were observed in the SP-A humanized mice in an allergic model, experiments were performed to find the active region of SP-A. It was determined that the active peptide is a 10 AA peptide that includes the 223Q site and is located in the carbohydrate recognition domain of endogenous SP-A. As shown in FIGS.
- SP-A deficient mice were challenged in the HDM model and 24 hrs after the last challenge, either a 20AA SP-A (PAGRGKEQCVEMYTDGQWND (SEQ ID NO: 8)) or a 10AA SP-A (KEQCVEMYTD (SEQ ID NO: 4)) was given and compared to those mice receiving vehicle treatment.
- Those mice receiving the SP-A peptides had significantly lower eosinophilia in the lavage compartment (FIG. 16A) and less mucin production (FIG. 16B) as compared to vehicle treated mice.
- SP-A peptides (10AA) that encompass the 223Q active site attenuate phenotypes in primary human airway epithelial cells from asthmatics.
- airway epithelial cells from two subjects with asthma not on controller therapy were cultured at air liquid interface for two weeks. In separate conditions the cells were exposed to each peptide at 20 pg/ml for 30 minutes followed by IL-13 at 50 ng/ml and incubated for 48 hours.
- Cells placed in Trizol MUCSAC were determined by RT-PCR.
- FIG. 17 shows a dramatic reduction in MUCSAC expression with each of the peptides to the level of negative control.
- the 10 AA length is especially useful as a therapeutic agent as its size renders it able to be packaged into an inhaler type of device for delivery to the airways.
- This experiment demonstrates that the 223Q peptide has efficacy in suppressing mucin gene expression in human airway epithelial cells in the setting of IL-13 exposure.
- mice were sensitized and challenged in the house dust mite (HDM) model according to standard methods on days 0, 7, 14 (black arrows). Twenty-four hours after the last challenge, mice received either scrambled vehicle or a 20-mer SP-A peptide (dotted arrow) that encompassed the active site containing 223Q (at a physiologic dose of 25 pg/mouse delivered in 40 pl of sterile saline) by oropharyngeal instillation. Lung histological sections were analyzed for mucin production as assessed by PAS stain/scoring to determine if the SP-A peptide could protect from HDM-induced airway mucin production. Similar protective effects were observed on days 5 and 7 after SP-A peptide treatment.
- PAGRGKEQCVEMYTDGQWND SEQ ID NO: 8).
- mice were sensitized and challenged in the house dust mite (HDM) model according to standard methods described in the aforementioned paragraph (see FIG. 5A). Twenty-four hours after the last challenge, mice received either scrambled vehicle, 20-mer, or 10-mer SP-A peptides (dotted arrow) that encompassed the active site containing 223Q (at a physiologic dose of 25 pg/mouse delivered in 40 pl of sterile saline) by oropharyngeal instillation.
- HDM house dust mite
- FIG. 6A lung histological sections were analyzed for mucin production as assessed by PAS stain/scoring to determine if the SP-A peptide could protect from HDM-induced airway mucin production. Similar protective effects were observed on days 5 and 7 after SP-A peptide treatment.
- FIG. 6B bronchoalveolar lavage samples were analyzed for eosinophilia to determine if the SP-A peptide could protect from HDM-induced airway eosinophilia by decreasing eosinophil viability. Viability was assessed by Trypan blue exclusion on a cell countess.
- Peptide sequences 20-mer PAGRGKEQCVEMYTDGQWND (SEQ ID NO: 8), peptide 1 PAGRGKEQCV (SEQ ID NO: 2), peptide 2 EMYTDGQWND (SEQ ID NO: 3), peptide 3 KEQCVEMYTD (SEQ ID NO: 4).
- FIG. 6C human bronchial epithelial cells obtained from well-phenotyped asthmatic participants by bronchoscopy were grown at ALI for two weeks prior to experimentation. For challenge, each of the SP-A test peptides (50 pg/ml) were added to the apical compartment at least 30 minutes prior to IL-13 challenge.
- Muc5AC was analyzed by RT-PCR from cell lysates and analyzed as a fold over the control samples.
- Peptide sequences 20-mer PAGRGKEQCVEMYTDGQWND (SEQ ID NO: 8), peptide 1 PAGRGKEQCV (SEQ ID NO: 2), peptide 2 EMYTDGQWND (SEQ ID NO: 3), peptide 3 KEQCVEMYTD (SEQ ID NO: 4)
- FL full length oligomeric SP-A that is extracted from lavage of alveolar proteinosis individuals.
- SP-A expression was analyzed from the bronchoalveolar lavage of lean, overweight and obese individuals with and without asthma by Western blot.
- FIGs. 5A-5D, 6A-6C, 15A-15B, and 18 show that SP-A223Q humanized mice have less mucus than the 223K mice in an allergic model (Ova model; FIGs. 15A-15B), that SP-A223Q humanized mice have less mucus than the 223K mice in an allergic model (HDM (house dust mite) model; FIGs. 5A-5D), that shortened 10AA peptides reduce mucin production in mouse HDM model (FIG. 6A), that shortened 10AA peptides reduce eosinophilia in mouse HDM model (FIG. 6B), that shortened 10AA peptides reduce Mucin (Muc5AC RNA) in human primary cells (FIG. 6C), and that SP-A is significantly decreased in obesity (FIG. 18).
- Example 2 describes the use of an HDM sensitization and challenge model in 10-12 adult primates that have been selected by pre-screening for baseline sensitivity to methacholine challenge to test SP-A therapeutic peptide in a crossover study design.
- HDM allergen is administered to all 10 primates by subcutaneous injection biweekly for 10 weeks, at which time animals are tested for HDM skin reactivity.
- HDM mask exposure is performed biweekly for a total of 8 weeks. After this HDM challenge period, airway hyperresponsiveness is assessed in all 12 primates and lavage fluid and biopsy specimens are collected for analysis.
- SP-A peptide and placebo are given biweekly via intranasal administration for four weeks, while primates are still receiving HDM mask treatments bi-weekly.
- the dosing of SP-A and placebo is approximately 24 hrs after the HDM mask exposure.
- Example 3 demonstrates that SP-A peptide protects against AHR in HDM (house dust mite) model.
- HDM house dust mite
- FIG. 10 WT C57BL/6 mice were sensitized and challenged in the HDM model according to standard methods (arrow). Twenty-four hours after each challenge, mice received either scrambled vehicle or a 10-mer SP-A peptide (KEQCVEMYTD (SEQ ID NO: 4)) (arrow) that encompassed the active site containing 223Q (at a physiologic dose of 25 mg/mouse delivered in 40 ml of sterile saline) by oropharyngeal instillation.
- KEQCVEMYTD SEQ ID NO: 4
- Pulmonary function tests were conducted 3-5 days post HDM challenge to determine if the SP-A peptide could protect from methacholine-induced airway hyper-responsiveness (AHR). Mice that received the SP-A peptide after HDM challenge had attenuated: overall resistance (Rrs) and central airways resistance (Rn) as compared to HDM challenged mice that received vehicle treatment. Similar protective effects were observed on days 3 and 5 after SP-A peptide treatment.
- Example 4 demonstrates that SP-A peptide protects against airway hyper-responsiveness (AHR) in IL-13 model.
- WT C57BL/6 mice were challenged with 3.9 ug of IL-13 (arrow) once a day for 3 consecutive days via oropharyngeal instillation.
- FIG. 7A-7E Two hours after each challenge, mice received either scrambled vehicle or a 10-mer SP-A peptide (KEQCVEMYTD (SEQ ID NO: 4)) (arrow) that encompassed the active site containing 223Q (at a physiologic dose of 25 mg/mouse delivered in 40 ml of sterile saline) by oropharyngeal instillation.
- KEQCVEMYTD SEQ ID NO: 4
- Pulmonary function tests were conducted 24 hours post IL-13 challenge to determine if the SP-A peptide could protect from methacholine-induced airway hyper-responsiveness (AHR). Mice that received the SP-A peptide after HDM challenge had attenuated: overall resistance (Rrs) and central airways resistance (Rn) as compared to HDM challenged mice that received vehicle treatment.
- Example 5 demonstrates that SP-A peptide protects against an SARS-CoV-2 infection.
- full-length SP-A binds to ACE2 in dose-dependent and CaCI2 dependent-manner.
- a 96- well plate assay was devised in which wells were coated with full-length human SP-A (500 ng/well) extracted from BAL obtained from alveolar proteinosis patients.
- lysates from HEK293T cells transfected with ACE2-expressing plasmids were added in varying concentrations.
- ACE2 was detected adding an anti-human ACE2 antibody and the developing substrate. Absorbance at 450 nm wavelength was read by plate reader.
- SP-A peptide mimetics derived from CRD compete with full-length SP-A for ACE2 binding. Both full-length SPA and SP-A 20-mer peptides competed for (i.e., inhibited) ACE binding to plate-bound SP-A, while a scrambled 20-mer peptide had no effect (FIG. 26).
- a specific variant at position 223 in SP-A2 is associated with lung phenotypes.
- SP-A containing a lysine at position 223 (223K) binds preferentially to the respiratory pathogen, Mycoplasma pneumoniae, as compared to when a glutamine is present at this position (223Q).
- peptides derived from this region have activity in various models of infection and inflammation as previously described herein.
- S1 protein binding assay was used. Cells were incubated with a recombinant His-tagged S1 subunit comprising the SARS-CoV-2 receptor binding domain, followed by a Alexa Fluor-conjugated anti-His antibody. S1 protein binding to cells was assessed by flow cytometry. The ability of this assay to specifically detect ACE2-mediated S1 protein cellular binding was validated using HEK293T cells, that were non-transfected or stably transfected with human ACE2 (ACE2/HEK293T).
- VSV-G-pseudotyped particles and SARS-CoV-2-pseudotyped particles efficiently transduced HEK293T ACE cells. While SP-A had little to no impact on VSV G-LUC transfection, SP-A dose-dependently reduced the transduction efficiency of SARSCoV-2 S protein-pseudotyped lentiviral particles (FIG. 28).
- SP-A attenuates SARS-CoV-2 N1 gene expression in a live infection model.
- Three-dimensional (3D) alveolar organoid cultures were established by resuspending fractioned HTII-280+ distal epithelial cells with MRC5 human lung fibroblast cells in a 50:50 (v/v) ratio of Matrigel and Pneumacult ALI medium in 24 well format transwell inserts according to common methods. Cultures were used for SARS-Co-V2 infection after 15-20 days. Prior to infection, Matrigel was dissolved by adding 500pL of Dispase (500pg/ml) to the apical and basement chambers of inserts and incubating for 1 hour at 37°C.
- Dispase 500pg/ml
- Cultures were harvested, washed with ice cold PBS and gently dispersed with a P1000 tip by pipetting up and down 3 times such that the organoids were ‘popped open’, exposing the apical surface of the cells.
- Organoids were treated by resuspending in 100 pL of media containing SP-A (50pg/ml ) per well. After 3 hrs of pretreatment, SARS-CoV-2 inoculum (1x10 A 4 TCID50 per well) was added to the cultures in a 2 ml conical tube and incubated for 2 hours at 37°C (5% CO2). Every 15 minutes, tubes were gently mixed to facilitate virus adsorption on the cells.
- inoculum was replaced with fresh Pneumacult ALI medium and cultures were transferred to the apical chamber of the insert in 100 pL volume with 500 pL of the medium in the basement chamber. Cultures were incubated at 37°C (5% CO2) and harvested at 2dpi. SP-A was maintained in the media for the duration of culture post infection. Organoids without drug treatment in the presence (CoV-2) or absence (mock) of viral infections were included as controls. Viral infection/replication was assessed by performing RT-qPCR for relative Nucleoprotein (N) gene expression using the 2019-nCoV_N1 primers obtained from the Center for Disease Control resources for research labs.
- N Nucleoprotein
- FIG. 30 shows SP-A 223Q and 223K 20-mer peptides reduced transduction of S1 protein-pseudotyped lentiviral particles in vitro to cells overexpressing ACE2.
- SP-A derived 20-mer peptides behaved similar to full-length SP-A in the ability to inhibit S protein-mediated SARS-CoV-2 entry into these cells was next investigated. Again, the entry of replication-deficient, SARSCoV-2 S1 protein-pseudotyped lentiviral particles into cells preincubated with SP-A, SP-A 223Q and 223K peptides or PBS were directly measured.
- the lentiviral particles carried a Luciferase reporter gene that is transcribed and translated by transduced cells, and were pseudotyped with SARS-CoV-2 S protein or the G glycoprotein of the pantropic VSV (positive transduction control).
- VSV-G-pseudotyped particles and SARS-CoV-2-pseudotyped particles efficiently transduced HEK293T ACE cells.
- SP-A 223 Q and 223K peptides dose-dependently reduced the transduction efficiency of SARSCoV-2 S protein-pseudotyped lentiviral, to a greater extent than full-length SP-A at each given concentration (FIG. 30).
- descriptions of the inventions described herein using the phrase “comprising” includes embodiments that could be described as “consisting essentially of or “consisting of, and as such the written description requirement for claiming one or more embodiments of the present invention using the phrase “consisting essentially of or “consisting of is met.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020247009792A KR20240052799A (en) | 2021-08-23 | 2022-08-23 | Compositions and methods for treating and preventing lung disease |
AU2022332283A AU2022332283A1 (en) | 2021-08-23 | 2022-08-23 | Compositions and methods for treating and preventing lung disease |
CA3175945A CA3175945A1 (en) | 2021-08-23 | 2022-08-23 | Compositions and methods for treating and preventing lung disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/409,642 US20210379141A1 (en) | 2016-04-11 | 2021-08-23 | Compositions and methods for treating and preventing lung disease |
US17/409,642 | 2021-08-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023028491A1 true WO2023028491A1 (en) | 2023-03-02 |
Family
ID=85322172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/075356 WO2023028491A1 (en) | 2021-08-23 | 2022-08-23 | Compositions and methods for treating and preventing lung disease |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023028491A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017180546A1 (en) * | 2016-04-11 | 2017-10-19 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating and preventing lung disease |
-
2022
- 2022-08-23 WO PCT/US2022/075356 patent/WO2023028491A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017180546A1 (en) * | 2016-04-11 | 2017-10-19 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating and preventing lung disease |
Non-Patent Citations (1)
Title |
---|
WATSON ALASTAIR, MADSEN JENS, CLARK HOWARD WILLIAM: "SP-A and SP-D: Dual Functioning Immune Molecules With Antiviral and Immunomodulatory Properties", FRONTIERS IN IMMUNOLOGY, FRONTIERS MEDIA, LAUSANNE, CH, vol. 11, 19 January 2021 (2021-01-19), Lausanne, CH , XP055819329, ISSN: 1664-3224, DOI: 10.3389/fimmu.2020.622598 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11110152B2 (en) | Compositions and methods for treating and preventing lung disease | |
CN110461351B (en) | Treatment of respiratory tract infections with TLR2 agonists | |
BR112021004420A2 (en) | dry powder formulation of caveolin-1 peptides and methods of use thereof | |
US20230190861A1 (en) | Peptide therapeutics for acute and chronic airway and alveolar diseases | |
BR112021004404A2 (en) | fragments of modified peptides of the cav-1 protein and their use in the treatment of fibrosis | |
JP2019512506A (en) | Combination of glucocorticoid and polyethylene glycol modified interleukin 2 for the treatment of respiratory diseases | |
US20230226149A1 (en) | Modified caveolin-1 peptides for the treatment of pathogen-induced lung injury | |
WO2023028491A1 (en) | Compositions and methods for treating and preventing lung disease | |
AU2022332283A1 (en) | Compositions and methods for treating and preventing lung disease | |
US20210379141A1 (en) | Compositions and methods for treating and preventing lung disease | |
RU2737799C1 (en) | Inhaled hexapeptide for treating respiratory diseases associated with interleukin-6 | |
JP2012505207A (en) | Pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease | |
US20230135877A1 (en) | Compositions and methods for treating and preventing lung disease | |
WO2023070069A1 (en) | Modified caveolin-1 peptides for the treatment of chronic kidney disease | |
BRPI0611710A2 (en) | airway administration of tissue factor step inhibitor in inflammatory conditions affecting the respiratory tract | |
US20220143147A1 (en) | Intranasal neuropeptides for use in stress-related impairments | |
US20240082342A1 (en) | Peptide therapeutics for increasing lung cell viability | |
US20240067713A1 (en) | Compositions and methods for treatment of chronic lung diseases | |
US20180344804A1 (en) | Attenuation of intrapulmonary inflammation | |
WO2021211006A1 (en) | Inhaled hexapeptide for treating interleukin-6 related respiratory diseases | |
WO2023154916A2 (en) | Compositions and methods for treating infectious diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22862231 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022332283 Country of ref document: AU Ref document number: 808515 Country of ref document: NZ Ref document number: AU2022332283 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2022332283 Country of ref document: AU Date of ref document: 20220823 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20247009792 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022862231 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022862231 Country of ref document: EP Effective date: 20240325 |